Episode Details
Back to Episodes
Hvivo Q&A: “this contract is important as it opens up new markets”
Episode 1899
Published 1 year, 9 months ago
Description
Watch on YouTube
Vox Markets speaks to Mo Khan, CEO of clinical research specialist Hvivo, about a new $2.5 million contract for an Omicron variant study to determine the virus dose needed to infect vaccinated individuals. This study will facilitate future human challenge trials to test vaccines and antivirals, with significant developments expected in 2025, expanding H Vivo’s market opportunities.
Vox Markets speaks to Mo Khan, CEO of clinical research specialist Hvivo, about a new $2.5 million contract for an Omicron variant study to determine the virus dose needed to infect vaccinated individuals. This study will facilitate future human challenge trials to test vaccines and antivirals, with significant developments expected in 2025, expanding H Vivo’s market opportunities.